dc.contributor.author | Koprivnikar, Blaz | |
dc.date.accessioned | 2016-12-22T22:27:47Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Koprivnikar, Blaz. Cost-Effectiveness Analyses of General Tar-geted Therapy in Non-Small Cell Lung Can-cer: a Systematic Review. Master thesis, University of Oslo, 2014 | |
dc.identifier.uri | http://hdl.handle.net/10852/53329 | |
dc.description.abstract | The thesis performs a systematic review of cost-effectiveness (CE) evaluation studies on targeted therapy procedures for non-small cell lung cancer (NSCLC). It identifies the work done in this field, establishes the relative comparisons and common approaches of CE studies of these treatments, gains a concluded under-standing of the topic, identifies potential areas for additional research, identifies shortcomings of examined CE studies, identifies which areas need additional in-vestigation and critiques the studies as well as suggests improvements. A total of 51 studies were found that matched the search words and inclusion criteria. 13 were finally included in the review. The overall quality of cost-effectiveness analyses on the subject was rather satisfactory. Data (immature data, lack of survival data), costs (not all costs included), discounting and overall as-sumptions of CEAs is where improvements could be made. In first-line treatment it was concluded erlotinib showed ambiguous results. Also in first-line treatment bevacizumab was shown as cost-effective. In the second-line therapy erlotinib was shown as cost-effective. On the basis of studies assessed tar-geted drugs appear to be a superior therapy. Erlotinib was compared to chemother-apy or placebo in most papers. | eng |
dc.language.iso | eng | |
dc.subject | non | |
dc.subject | small | |
dc.subject | cell | |
dc.subject | lung | |
dc.subject | cancer | |
dc.subject | NSCLC | |
dc.subject | bevacizumab | |
dc.subject | erlotinib | |
dc.subject | cetuximab | |
dc.subject | afatinib | |
dc.subject | crizotinib | |
dc.subject | gefitinib | |
dc.subject | targeted | |
dc.subject | cost | |
dc.subject | effectiveness | |
dc.title | Cost-Effectiveness Analyses of General Tar-geted Therapy in Non-Small Cell Lung Can-cer: a Systematic Review | eng |
dc.type | Master thesis | |
dc.date.updated | 2016-12-28T22:27:29Z | |
dc.creator.author | Koprivnikar, Blaz | |
dc.date.embargoenddate | 3014-06-13 | |
dc.rights.terms | Dette dokumentet er ikke elektronisk tilgjengelig etter ønske fra forfatter. Tilgangskode/Access code A | |
dc.identifier.urn | URN:NBN:no-56570 | |
dc.type.document | Masteroppgave | |
dc.rights.accessrights | closedaccess | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/53329/1/Master-Thesis--Blaz-Koprivnikar--June-2014.pdf | |